Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 305.

https://doi.org/10.1182/blood.V118.21.305.305

Published: 2011

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher A. Chanan-Khan, MD, Leonard T Heffner, MD, David Avigan, MD, Robert J Lutz, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Thomas Haeder, PhD, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2010) 116 (21): 3060.

https://doi.org/10.1182/blood.V116.21.3060.3060

Published: 2010

Journal Articles

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Chantal Zuber, PhD, Benjamin Daelken, PhD, Silke Aigner, PhD, Thomas Haeder, PhD, Olga Ab, PhD, Kathleen Whiteman, PhD, Teru Hideshima, Robert J Lutz, PhD, Frank Osterroth, PhD, Christoph Uherek, PhD

Blood (2010) 116 (21): 3008.

https://doi.org/10.1182/blood.V116.21.3008.3008

Published: 2010

Journal Articles

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Leonard T. Heffner, David Avigan, MD, Kelvin P. Lee, MD, Robert J Lutz, PhD, Thomas Haeder, PhD, Markus Ruehle, MD, Christoph Uherek, PhD, Andrea Barbara Wartenberg-Demand, MD, Nikhil Munshi, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1862.

https://doi.org/10.1182/blood.V114.22.1862.1862

Published: 2009

Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Blood (2008) 112 (11): 1716.

https://doi.org/10.1182/blood.V112.11.1716.1716

Published: 2008

Journal Articles

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.

Annette Romanski, Christoph Uherek, Gesine Bug, Tina Muller, Claudia Rossig, Manuela Kampfmann, Nicola Krossok, Dieter Hoelzer, Erhard Seifried, Winfried Wels, Oliver G. Ottmann, Torsten Tonn

Blood (2004) 104 (11): 2747.

https://doi.org/10.1182/blood.V104.11.2747.2747

Published: 2004

Journal Articles

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Christoph Uherek, Torsten Tonn, Barbara Uherek, Sven Becker, Barbara Schnierle, Hans-Georg Klingemann, Winfried Wels

Blood (2002) 100 (4): 1265–1273.

https://doi.org/10.1182/blood.V100.4.1265.h81602001265_1265_1273

Published: 2002

NARROW

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Email alerts

ASH Publications

American Society of Hematology

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only